Multiple Sclerosis

Multiple Sclerosis - Focus on Mental Health

Depression is commonly observed in people with MS, with approximately 25% to 50% of all patients being affected.¹ Depression, whether diagnosed or not, can correlate with decreased adherence to prescribed treatments for MS.² Treatment for depression can include pharmacotherapy, psychotherapy, or cognitive behavioral therapy.³ Treating depression can improve disease modifying therapy adherence, fatigue, and quality of life.³

Patients With Depression Screening by PHQ-9

2020 – 2021

In 2021, 77.7% (N = 1981) of patients were screened for depression by PHQ9.

Patients With Concern for Depression (PHQ-9 ≥ 10)

2020 – 2021

In 2021, 28.1% (N = 717) of screened patients had PHQ9 scores concerning for depression (PHQ9 ≥ 10).

Patients Treated With Pharmacotherapy or Psychotherapy

2020 – 2021

In 2021, 66.3% (N = 475) of the patients with PHQ9 scores concerning for depression were treated with pharmacotherapy or psychotherapy.

  1. Marck CH, Hunter A, Butler E, et al. Assessment and treatment of depression in people with multiple sclerosis: A qualitative analysis of specialist clinicians' experiences. Mult Scler Relat Disord. 2022 Jan;57:103362.
  2. Washington F, Langdon D. Factors affecting adherence to disease-modifying therapies in multiple sclerosis: systematic review. J Neurol. 2022 Apr;269(4):1861-1862.
  3. Skokou M, Soubasi E, Gourzis P. Depression in multiple sclerosis: A review of assessment and treatment approaches in adult and pediatric populations. ISRN Neurol. 2012;2012:427102.